Cancer News and Research

Latest Cancer News and Research

Experimental treatment for multiple sclerosis reverses disorder in mice

A new experimental treatment for multiple sclerosis (MS) completely reverses the devastating autoimmune disorder in mice, and might work exactly the same way in humans, say researchers at the Jewish General Hospital Lady Davis Institute for Medical Research and McGill University in Montreal.

11 Aug 2009

Hospira launches generic version of Sanofi-Aventis' Eloxatin

Hospira, Inc. (NYSE: HSP) today announced U.S. Food and Drug Administration (FDA) approval and launch of oxaliplatin injection in the United States.

11 Aug 2009

Aldose reductase inhibition shows promise for asthma

University of Texas Medical Branch at Galveston researchers have found that a single enzyme is apparently critical to most allergen-provoked asthma attacks - and that activity of the enzyme, known as aldose reductase, can be significantly reduced by compounds that have already undergone clinical trials as treatments for complications of diabetes.

11 Aug 2009

Canadian health care: Socialized insurance, not socialized medicine

"Amid the debate about reforming heath care in the United States, it's tough to turn on your television these days without hearing a political ad condemning the Canadian health care system," NPR reports. While those ads are "provocative," NPR asks whether they accurately portray Canadian health care.

11 Aug 2009

Regular use of aspirin after colorectal cancer diagnosis may reduce the risk of cancer death

In the August 12 issue of the Journal of the American Medical Association, the study's authors also find that the aspirin-associated survival advantage was seen primarily in patients with tumors expressing the COX-2 enzyme, a characteristic of two-thirds of colorectal cancers.

11 Aug 2009

High-fat diet affects physical and memory abilities of rats after 9 days

Rats fed a high-fat diet show a stark reduction in their physical endurance and a decline in their cognitive ability after just nine days, a study by Oxford University researchers has shown.

11 Aug 2009

$Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer$

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.

11 Aug 2009

Nurses harnessing the power of wireless technologies and online communities

The Johns Hopkins University School of Nursing (JHUSON) is harnessing the power of wireless technologies and online communities to help nurses throughout the world “connect for health.” Under the direction of Associate Professor Patricia A. Abbott, PhD, RN, FAAN, the School’s Global Alliance for Nursing and Midwifery Community of Practice (GANM) has become a teacher for the 21st century, speeding new health information and know-how to nurses around the globe—from the most urbanized, high-tech cities to the most remote villages, using low bandwidth telecommunication technologies.

11 Aug 2009

Stress management to male nursing in Johns Hopkins Nursing Summer issue

The birth of a baby. A diagnosis of breast cancer. The frailty that comes with old age. They are part of the dynamic, complex, and ever-changing landscape that makes up a women's life span. Whatever the ailment, Hopkins nurses are empowering women to embrace healthier lifestyles.

11 Aug 2009

Upstream Biosciences actively seeking licensors or acquirers for anti-parasitic drug discovery portfolio and cancer diagnostic platform

Upstream Biosciences Inc. (OTCBB: UPBS) has announced that the company is actively seeking licensors or acquirers for its novel anti-parasitic drug discovery portfolio and cancer diagnostic platform.

11 Aug 2009

Seattle Genetics reaches milestone under collaboration agreement with MedImmune

Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration agreement with MedImmune, LLC, a wholly owned subsidiary of AstraZeneca. The milestone was triggered by MedImmune’s initiation of a phase I clinical trial of MEDI-547, its anti-EphA2 ADC for solid tumors.

11 Aug 2009

Oxygen nanosensor could improve tumor imaging

A new material developed at the University of Virginia - an oxygen nanosensor that couples a light-emitting dye with a biopolymer - simplifies the imaging of oxygen-deficient regions of tumors. Such tumors are associated with increased cancer aggressiveness and are particularly difficult to treat.

11 Aug 2009

Researchers launch study into search-and-destroy antigen for deadly skin cancer

UT Southwestern Medical Center researchers are studying a new antigen to see whether it can track down and kill cancer cells in patients with recurring melanoma, the leading cause of skin cancer deaths.

11 Aug 2009

Holography helps tackle ovarian cancer

Two University of Arizona researchers have formed a research team to design, build and evaluate two versions of an ovarian cancer medical imaging and screening instrument that will use holographic components in a new type of optical microscope.

11 Aug 2009

Easy-to-swallow drug restores autoimmune function in diabetics

Found in 30% of all human cancer tumors, the Ras protein literally "drives cells crazy," says Prof. Yoel Kloog, the dean of the Faculty of Life Sciences at Tel Aviv University. Prof. Kloog was the first in the world to develop an effective anti-Ras drug against pancreatic cancer, currently in clinical trials. Now, new research published in the June issue of the European Journal of Pharmacology shows that the drug might be able to slow the progression of diabetes as well.

11 Aug 2009

Genzyme updates on Cerezyme supply plus 2009 financials

Genzyme Corporation (NASDAQ: GENZ) today provided an update on the impact of Cerezyme® (imiglucerase for injection) supply constraints on patient treatment regimens and on the company’s 2009 financial results. The company’s Fabrazyme® (agalsidase beta) supply constraint period, Fabrazyme dose conservation guidelines for patients, and Fabrazyme financial guidance are unchanged.

11 Aug 2009

Predictors of disease behavior change in patients with Crohn's disease

Using the Vienna classification system, it has been shown in clinic-based cohorts that there can be a significant change in disease behavior over time, whereas disease location remains relatively stable. Clinical and environmental factors as well as medical therapy might be relevant in predicting disease behavior change in patients with CD.

11 Aug 2009

Characteristic pathological findings and effects of ecabet sodium in rat reflux esophagitis

Recently, the number of patients with GERD has increased in Japan. However, there have been few reports about the pathological findings in the esophageal squamous epithelium, and there are differing opinions among pathologists about the findings considered characteristic of chronic reflux esophagitis.

11 Aug 2009

STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells

In a study published online in advance of print in Stem Cells, Tufts researchers report that the STAT3 gene regulates cancer stem cells in brain cancer. Cancer stem cells have many characteristics of stem cells and are thought to be the cells that drive tumor formation. The researchers report that STAT3 could become a target for cancer therapy, specifically in Glioblastoma multiforme (GBM), a type of malignant and aggressive brain tumor.

11 Aug 2009

Importance of PSA testing in high-risk men, stressed by National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Prostate Cancer Early Detection incorporating the results of the recent ERSPC trial that assessed the benefit of PSA screening. The NCCN Guidelines contend that PSA screening does save lives when performed intelligently in men at high-risk of developing the disease.

11 Aug 2009